Lilly is committed to doing everything possible to bring the full force of their scientific and medical expertise to attack the coronavirus pandemic. The company announced it has entered into an agreement with AbCellera to co-develop antibodies for the potential treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies.
Additionally, Lilly scientists are partnering with the Indiana State Department of Health, with support from the FDA, to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19. Lilly is using its specialized research laboratories to analyze samples taken in Indiana health care facilities, including nursing homes and emergency rooms. In addition, Lilly has launched a drive-through testing facility at their corporate headquarters for active front-line health care workers and Indianapolis first responders, as a service to the community and in an effort to protect people working on the front lines of this epidemic. On April 1, Lilly announced it is expanding testing to two new groups of higher-risk individuals: workers in businesses deemed essential by the State of Indiana who have regular public contact as part of their job, and people in the community showing symptoms who are vulnerable to severe complications of the virus. Lilly hopes that expanding testing in these populations will make a meaningful difference in this fight – for both individuals and health care providers as they battle this virus on the front lines. Lilly will not accept payment from government agencies, hospitals, insurance companies or patients for conducting or analyzing tests.
Lilly is also closely monitoring their supply chain and does not currently anticipate shortages for any of their medicines, including all forms of insulin. Additionally, Lilly and the Lilly Foundation are actively engaged with community partners to address new and complex challenges arising from the coronavirus, including the economic impact on vulnerable people. Find the latest information on Lilly’s efforts here.
New $35 co-pay now available through Lilly Insulin Value Program in response to COVID-19 crisis in U.S. Learn more here.